Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease.

Deneau M, Wallentine J, Guthery S, O'Gorman M, Bohnsack J, Fluchel M, Bezzant J, Pohl JF.

Pediatrics. 2010 Oct;126(4):e977-81. doi: 10.1542/peds.2010-0486.

PMID:
20837584
2.

Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as Gastrointestinal Perforations and Skin Lesions: A Case Report.

Xiao HJ, Li J, Song HM, Li ZH, Dong M, Zhou XG.

Medicine (Baltimore). 2016 Feb;95(5):e2676. doi: 10.1097/MD.0000000000002676. Erratum in: Medicine (Baltimore). 2016 Apr;95(15):e7342.

3.

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Review.

PMID:
24462626
4.

EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?

Allen PB, Laing G, Connolly A, O'Neill C.

BMJ Case Rep. 2013 Sep 30;2013. pii: bcr2013200423. doi: 10.1136/bcr-2013-200423.

5.

Extranodal natural killer/T-cell lymphoma, nasal-type.

Chorianopoulos D, Samitas K, Vittorakis S, Kiriazi V, Rondoyianni D, Tsaousis G, Skoutelis A.

Skinmed. 2010 Jan-Feb;8(1):56-8.

PMID:
20839428
7.

Primary central nervous system extranodal NK/T cell lymphoma, nasal type, with antecedent hemophagocytic syndrome in a child.

Jiang X, Yin W, Song J, Chen X, Zhao C, Wen F.

Pediatr Dev Pathol. 2014 Nov-Dec;17(6):482-6. doi: 10.2350/14-02-1441-CR.1. Review.

PMID:
25207703
8.

Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.

de Vries HS, van Oijen MG, de Jong DJ.

Drug Saf. 2008;31(12):1135-44. doi: 10.2165/0002018-200831120-00009.

PMID:
19026030
9.
10.

Infliximab therapy in children and adolescents with inflammatory bowel disease.

Veres G, Baldassano RN, Mamula P.

Drugs. 2007;67(12):1703-23. Review.

PMID:
17683171
11.

The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.

Sandhu A, Alameel T, Dale CH, Levstik M, Chande N.

Aliment Pharmacol Ther. 2012 Jul;36(2):159-65. doi: 10.1111/j.1365-2036.2012.05141.x.

12.

Safety of infliximab and other biologic agents in the inflammatory bowel diseases.

Reddy JG, Loftus EV Jr.

Gastroenterol Clin North Am. 2006 Dec;35(4):837-55. Review.

PMID:
17129816
13.

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H, Graninger W, Tilg H, Reinisch W; Austrian Society of Gastroenterology and Hepatology..

J Crohns Colitis. 2010 Sep;4(3):221-56. doi: 10.1016/j.crohns.2009.12.001.

14.

Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.

Subramaniam K, D'Rozario J, Pavli P.

J Gastroenterol Hepatol. 2013 Jan;28(1):24-30. doi: 10.1111/jgh.12015. Review.

PMID:
23094824
15.

Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.

Wang RC, Chang ST, Hsieh YC, Huang WT, Hsu JD, Tseng CE, Wang MC, Hwang WS, Wang J, Chuang SS.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2430-7.

16.

Cutaneous peripheral T-cell lymphoma of cytotoxic phenotype mimicking extranodal NK/T-cell lymphoma.

Pan ST, Chang WS, Murphy M, Martinez A, Chuang SS.

Am J Dermatopathol. 2011 Apr;33(2):e17-20. doi: 10.1097/DAD.0b013e3181ea6571.

PMID:
21252637
17.

Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.

Adler J, Sandberg KC, Shpeen BH, Eder SJ, Dhanani M, Clark SJ, Freed GL.

J Pediatr Gastroenterol Nutr. 2013 Jul;57(1):35-8. doi: 10.1097/MPG.0b013e31828f1ea2.

PMID:
23459317
18.

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P.

Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642.

PMID:
18832524
19.

Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders.

Nissen LH, Nagtegaal ID, de Jong DJ, Kievit W, Derikx LA, Groenen PJ, van Krieken JH, Hoentjen F.

J Crohns Colitis. 2015 May;9(5):398-403. doi: 10.1093/ecco-jcc/jjv040.

PMID:
25740811
20.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228

Supplemental Content

Support Center